Prescription of hazardous drugs during pregnancy

Drug Safety

Volumn 27, Issue 12, 2004, Pages 899-908

  Malm, Heli ^a,b   Martikainen, Jaana ^c   Klaukka, Timo ^c   Neuvonen, Pertti J ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c SOCIAL INSURANCE INSTITUTION   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANDROGEN; ANTICONVULSIVE AGENT; ANTIMETABOLITE; BUSERELIN; CARBAMAZEPINE; CARBIMAZOLE; CHORIONIC GONADOTROPIN; CLOMIFENE; CORTICOSTEROID; COUMARIN DERIVATIVE; DICLOFENAC; FLUCONAZOLE; FLUTICASONE PROPIONATE; IBUPROFEN; KETOPROFEN; LITHIUM; MISOPROSTOL; NAFARELIN; NAPROXEN; PENICILLAMINE; PHENYTOIN; PIVMECILLINAM; RETINOID; TERATOGENIC AGENT; THALIDOMIDE; TIZANIDINE; TOLFENAMIC ACID; UNINDEXED DRUG; VALPROIC ACID;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DRUG ABUSE; DRUG CLASSIFICATION; DRUG SAFETY; DRUG USE; FEMALE; FINLAND; FIRST TRIMESTER PREGNANCY; HUMAN; PATIENT COUNSELING; POLYPHARMACY; PRACTICE GUIDELINE; PREGNANCY; PRENATAL CARE; PRESCRIPTION; PRIORITY JOURNAL; REGISTER; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SECOND TRIMESTER PREGNANCY; TERATOGENESIS; THIRD TRIMESTER PREGNANCY; TREATMENT PLANNING;

ADMINISTRATION, INTRANASAL; COHORT STUDIES; DEMOGRAPHY; DRUG LABELING; DRUG UTILIZATION REVIEW; FEMALE; FINLAND; FORECASTING; HUMANS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PHARMACEUTICAL PREPARATIONS; POLYPHARMACY; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PRESCRIPTIONS, DRUG; REGISTRIES; RETROSPECTIVE STUDIES; TERMINOLOGY; TREATMENT OUTCOME;

EID: 4944264214     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200427120-00006     Document Type: Article

References (25)

1. Kalter H. Environmental causes of congenital malformations in humans and how they were established. Neurotoxicol Teratol 2003; 25: 131-282
2. Webster WS, Freeman JA. Prescription drugs and pregnancy. Expert Opin Pharmacother 2003; 4: 949-61
3. Addis A, Sharabi S, Bonati M. Risk classification systems for drug use during pregnancy: are they a reliable source of information? Drug Saf 2000; 23 (3): 245-53
4. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 5th ed. Baltimore (MD): Lippincott Williams & Wilkins, 1998
5. Doering PL, Boothby LA, Pharm D, et al. Review of pregnancy labeling of prescription drugs: is the current system adequate to inform of risk? Am J Obstet Gynecol 2002; 187: 333-9
6. Sannerstedt R, Lundborg P, Danielsson BR, et al. Drugs during pregnancy: an issue of risk classification and information to prescribers. Drug Saf 1996; 14 (2): 69-77
7. FASS. Classification of medical products for use during pregnancy and lactation. The Swedish system. Stockholm: LINFO, Drug Information Ltd, 1993
8. Australian Drug Evaluation Committee. Medicines in pregnancy: an Australian categorisation of risk of drug use in pregnancy. 3rd edition. Canberra; Australian Government Publishing Service, 1996
9. Malm H, Martikainen J, Klaukka T, et al. Prescription drugs during pregnancy and lactation: a Finnish register-based study. Eur J Clin Pharmacol 2003; 59: 127-33
10. De Vigan C, De Walle HC, Cordier S, et al. Therapeutic drug use during pregnancy: a comparison in four European countries. J Clin Epidemiol 1999; 52: 977-82
11. Donati S, Baglio G, Spinelli A, et al. Drug use in pregnancy among Italian women. Eur J Clin Pharmacol 2000; 56: 323-8
12. Olesen C, Hald Steffensen F, Nielsen GL, et al. Drug use in first pregnancy and lactation: a population-based survey among Danish women. Eur J Clin Pharmacol 1999; 55: 139-44
13. Lacroix I, Damase-Michel C, Lapeyre-Mestre M, et al. Prescription of drugs during pregnancy in France. Lancet 2000; 356: 1735-6
14. Headley J, Northstone K, Simmons H, et al. Medication use during pregnancy: data from the Avon Longituninal Study of Parents and Children. Eur J Clin Pharmacol 2004; 60: 335-61
15. Olesen C, Sondergaard C, Thrane N, et al. Do pregnant women report use of dispensed medications? Epidemiology 2001; 12: 497-501
16. Olesen C, Sorensen HT, de Jong-van den Berg L, et al. Prescribing during pregnancy and lactation with reference to the Swedish classification system: a population-based study among Danish women. The Euromap Group. Acta Obstet Gynecol Scand 1999; 78: 686-92
17. Schirm E, Meijer WM, Tobi H, et al. Drug use by pregnant women and comparable non-pregnant women in the Netherlands with reference to the Australian classification system. Eur J Obstet Gyn 2004; 114: 182-8
18. Källen B, Rydhström H, Åberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol 1999; 93: 392-5
19. Bianca S. Drug use during pregnancy: are risk classifications more dangerous than the drugs? [letter]. Lancet 2003; 362: 329
20. FASS. Farmaceutiska Specialiteter i Sverige. Lakemedel i Sverige. LINFO. Oslo; Elanders Publishing, 1999
21. Christensen B. Which antibiotics are appropriate for treating bacteriuria in pregnancy? J Antimicrob Chemother 2000; 46 Suppl. 1: 29-34
22. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998; 338: 1128-37
23. Nulman I, Berkovitch M, Klein J, et al. Steady-state pharmacokinetics of isotretinoin and its 4-oxo metabolite: implications for fetal safety. J Clin Pharmacol 1998; 38: 926-30
24. Balasubramaniam J. Nimesulide and neonatal failure [letter]. Lancet 2000; 355: 575
25. Pennell PB. The importance of monotherapy during pregnancy. Neurology 2003; 60 Suppl. 4: 31-8